$DNLI News

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40

Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23

Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34

Denali Therapeutics shares are trading higher after the company announced it secured $200 million in gross proceeds under the Royalty Agreement.

Denali Therapeutics shares are trading higher after the company announced it secured $200 million in gross proceeds under the Royalty Agreement.

Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow

Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42

Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40

Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41

Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32

HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript

FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript